Publications by authors named "Y Goueffic"

Article Synopsis
  • Endovascular interventions using Luminor, a nanotechnology-based drug-coated balloon (DCB), have shown effectiveness in treating femoropopliteal lesions, with a large-scale study called the LUMIFOLLOW registry evaluating its real-world performance after it succeeded in prior trials like Effpac.
  • The LUMIFOLLOW study involved 542 patients with various comorbidities and lesion types, focusing on safety and efficacy, with primary endpoints including freedom from major complications and target lesion revascularization.
  • Results indicated a high procedural success rate of 99.4%, although some patients required stenting and there were minor adverse events, suggesting the treatment is generally effective but may need further assessment in complicated
View Article and Find Full Text PDF

Objectives: Percutaneous old balloon angioplasty is still the preferred treatment for the treatment of below-the-knee (BTK) arteries in chronic limb-threatening ischemia (CLTI). In the case of a suboptimal angioplasty result, a bailout stenting is required. So far, few data are available to assess the outcomes of bailout stenting after BTK angioplasty.

View Article and Find Full Text PDF

Background: Endovascular treatment of the common femoral artery (CFA) and its bifurcation is currently recommended for patients with hostile groin (prior femoral bifurcation open surgery, history of radiotherapy) or severe comorbidities (advanced age, frailty, obesity). Preliminary results have shown favorable outcomes. Among the different endovascular techniques (atherectomy, intravascular lithotripsy, plain balloon angioplasty, drug-coated balloon angioplasty, stenting), stents are mainly used but the best type of stent to use is still debated.

View Article and Find Full Text PDF

Peripheral arterial disease is the third leading cause of cardiovascular morbidity after coronary artery disease and stroke. Lower limb peripheral arterial disease commonly involves infrainguinal arteries, may impair walking ability (intermittent claudication) and may confer a significant risk of limb loss (chronic limb-threatening ischaemia), depending on the severity of ischaemia. Endovascular treatment has become the mainstay revascularisation option in both the femoropopliteal and the below-the-knee arterial segments.

View Article and Find Full Text PDF